Stock Analiz

Sol-Gel Technologies Ltd. SLGL

Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026

$55.12Market cap $180M
Open the interactive analysis →

Sol-Gel Technologies Ltd. (SLGL) is a healthcare company listed in the US with a market value of about $180M. In fiscal year 2025 it had revenue of $19M and net income of -$6M, a net margin of -31.6%.

Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: a price to free cash flow of 656.2, 5-year revenue growth of 17% a year, a 5-year average ROIC of -28%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Sol-Gel Technologies

Sol-Gel Technologies is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $174000 in 2017 to $19M in 2025, growth of about 80.2% a year. It was profitable in 1 of the last 10 years in our data. It spends 118% of revenue on research and development.

Score: 2.0 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health4/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF656.2
P/S100.5
P/B3.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield0.1%
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)68.0%
Revenue growth (5 yrs, per year)17.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-450.0%
ROIC (5-yr avg.)-27.7%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$19M$12M$2M$4M$31M$9M$23M$129000$174000—
Net income-$6M-$11M-$27M-$15M$3M-$29M-$25M-$32M-$32M-$21M
Free cash flow$275000-$14M-$18M-$10M-$8M-$26M-$23M-$25M-$26M-$19M
EPS (diluted)$-1.87$-3.23$-8.32$-4.56$0.98$-8.95$-7.52$-9.84$-9.64$-6.34
Net margin-31.6%-91.7%-1752.8%-384.3%10.3%-333.9%-107.4%-24963.6%-18142.5%—
ROIC-25.0%-31.5%-57.5%-29.8%5.2%-58.0%-38.1%-41.4%-197.7%-273.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $155.50, 182% above the current price; targets range from $110.00 to $201.00; the consensus rating is “Strong buy”; expected EPS is $-11.80 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Sol-Gel Technologies stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Sol-Gel Technologies pay a dividend?

Not currently.

Is Sol-Gel Technologies a good stock to buy?

We do not give buy or sell advice. Sol-Gel Technologies scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.